1. Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant.
- Author
-
Kaku Y, Uriu K, Okumura K, Ito J, and Sato K
- Subjects
- Humans, SARS-CoV-2 genetics, COVID-19 virology, COVID-19 epidemiology
- Abstract
Competing Interests: JI received consulting fees and honoraria for lectures from Takeda; consulting fees from Moderna and Takeda; and honoraria for lectures from Moderna and Shionogi. The other authors declare no competing interests. This study was supported in part by AMED ASPIRE Program (JP24jf0126002 to G2P-Japan Consortium and KS); AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers “UTOPIA” (JP243fa627001h0003 to KS); AMED SCARDA Program on R&D of new generation vaccine including new modality application (JP243fa727002 to KS); AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP24fk0108690 to KS); JST PRESTO (JPMJPR22R1 to JI); JSPS KAKENHI Fund for the Promotion of Joint International Research (International Leading Research; JP23K20041 to G2P-Japan Consortium and KS); JSPS KAKENHI Grant-in-Aid for Early-Career Scientists (JP23K14526 to JI); JSPS KAKENHI Grant-in-Aid for Scientific Research A (JP24H00607 to KS); Mitsubishi UFJ Financial Group, Inc. Vaccine Development Grant (to JI and KS); and The Cooperative Research Program (Joint Usage/Research Center program) of Institute for Life and Medical Sciences, Kyoto University (to KS).
- Published
- 2024
- Full Text
- View/download PDF